The capital expenditure of Rs 2,800 crore incurred at its existing sites would cater to the pharma company’s growth over the next 12-24 months, while the spend at the Kakinada unit would drive growth beyond FY25, the brokerage firm has said
The capital expenditure of Rs 2,800 crore incurred at its existing sites would cater to the pharma company’s growth over the next 12-24 months, while the spend at the Kakinada unit would drive growth beyond FY25, the brokerage firm has said The capital expenditure of Rs 2,800 crore incurred at its existing sites would cater to the pharma company’s growth over the next 12-24 months, while the spend at the Kakinada unit would drive growth beyond FY25, the brokerage firm has said Moneycontrol Latest News Read More
English 
हिन्दी